Entry into a Material Definitive Agreement. On March 19, 2026, Genelux Corporation (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), pursuant to which the Company may, from time to time, offer and sell shares of the Company’s common stock, par value $0.001 per share (the “Placement Shares”), having an aggregate offering price of up to $100,000,000, through TD Cowen, acting as the Company’s sales agent and/or principal. The Placem…

Other Events. Underwritten Public Offering On January 8, 2026, Genelux Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC ( the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten offering (the “Offering”) an aggregate of 6,666,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $3.00 per share. A…

Other Events. On January 5, 2026, Genelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer and progressive non-small cell lung cancer, respectively, after failure of prior platinum-based regimens. Platinum-relapsed or platinum-refractory advanced SCLC (Phase 1b/2 SCLC trial) The open-label Phase 1b/2 SCLC trial ( NCT07136285 ) is evaluating a single intravenous cycle with multiple…

Chief Medical Officer — Paul Scigalla, M.D.: Dr. Paul Scigalla resigned as Chief Medical Officer.

The filing describes a reduction in the exercise prices of certain outstanding stock options and an annual meeting where directors were elected.

Other Events. On March 25, 2025, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group, a division of American Capital Partners (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten registered direct offering (the “Offering”) an aggregate of 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $3.50 per share. T…

Results of Operations and Financial Condition. Genelux Corporation (the “Company”) estimates that its cash, cash equivalents and short-term investments as of December 31, 2024 were approximately $30.9 million. The Company has not yet completed its quarter-end or year-end financial close process for the quarter and year ended December 31, 2024. This estimate of the Company’s cash, cash equivalents and short-term investments as of December 31, 2024 is preliminary, has not been audited and is su…

Vice President, Head of Quality — Caroline Jewett: Caroline Jewett resigned as Vice President, Head of Quality.

Other Events. On June 3, 2024, the Underwriters (as defined below) exercised in part their option to purchase (i) an additional 625,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) accompanying warrants to purchase 625,000 shares of Common Stock (the “Warrants”), with an exercise price of $5.25 per share, at a combined offering price of $4.00 per share and accompanying Warrant, pursuant to an underwriting agreement dated as of M…

Entry into a Material Definitive Agreement. On May 23, 2024, Genelux Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (i) 6,875,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) accom…

is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. Forward-Looking Stateme…

Results of Operations and Financial Condition. The information set forth below in

VP, Finance — Doug Samuelson: Doug Samuelson resigned as VP, Finance of Genelux Corporation.

The filing describes the adoption of a new compensatory plan for future hires.

Director — Gabe Woodward: Mr. Woodward resigned from the Board due to his partnership's request after the Company’s initial public offering was completed.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Reference is made to

Unregistered Sales of Equity Securities. The disclosure regarding the securities to be sold and issued under the Purchase Agreement as set forth under

Entry into a Material Definitive Agreement. Private Placement of Common Stock On June 9, 2023, Genelux Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue 900,000 shares of the Company’s common stock (“Common Stock”) in a private placement transaction (the “Private Placement”). The purchase price per share of Common Stock is $20.00 per share. The in…

Thomas Zindrick: The filing describes a new employment agreement for the current CEO, President, and Chairman.